IQVIA Holdings, Inc. (IQV) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is modestly constructive — consensus is a manageable bar, guidance is well-defined, and peer read-throughs from ICON and Medpace both point to a healthy Q2 CRO demand environment; the single biggest swing factor is whether R&DS net bookings and book-to-bill recover meaningfully from Q1’s pass-through-depressed 1.04x.

Heading into Q2 2026 results, IQVIA’s setup is the most constructive it has been in several quarters. Management guided Q2 revenue to $4.280–$4.340 billion (consensus sits at $4.302 billion, squarely in-range), adjusted EBITDA to $955–$975 million (consensus $967 million), and adjusted diluted EPS to $2.98–$3.08 (consensus $3.03) — a bar that is neither stretched nor sandbagged. The tone from the Q1 call was unambiguously positive: management described being “surprised” by the strength across every metric, raised full-year EPS guidance, and disclosed that April 2026 EBP funding was approximately triple April 2025 levels — the strongest leading-indicator signal in years. Estimate revisions since the Q1 print have been essentially flat (Q2 EPS consensus moved from $3.034 to $3.031, FY EPS from $12.816 to $12.810), suggesting the street has not yet fully priced in the improving demand backdrop and leaves room for a positive surprise. The stock has rallied ~21% since the May 5 earnings date but still trades at only ~15x NTM P/E versus historical averages, implying the multiple has not fully re-rated despite improving fundamentals. The key wildcard is the Q2 book-to-bill: Q1’s 1.04x drew scrutiny (management attributed it entirely to unusually low pass-throughs), and a recovery toward the 1.10–1.15x range — consistent with peer ICON’s expectation of a “notably strong signing quarter” and Medpace’s record net bookings in Q2 — would be the single most powerful catalyst for multiple re-rating.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable, in-guidance bar across all key metrics; the bigger swing factor is R&DS net bookings and book-to-bill, where a recovery from Q1’s pass-through-depressed 1.04x would be the most meaningful positive catalyst for the stock.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. Q2 2026 guidance midpoints derived from IQVIA Q1 2026 earnings call (May 5, 2026): Revenue $4.280–$4.340B midpoint = $4.310B; Adj. EBITDA $955–$975M midpoint = $965M; Adj. Diluted EPS $2.98–$3.08 midpoint = $3.030. Q1 2026 Actual and Q2 2025 Actual sourced from Visible Alpha.

Table 2 — Beat/Miss History (Last 8 Quarters)

Top KPI #1: Total Revenue

IQVIA has beaten revenue consensus in each of the last 8 consecutive quarters, with surprise magnitudes ranging from +0.5% to +2.9% — a remarkably consistent pattern that sets a high bar for Q2 2026.

Top KPI #2: Adjusted Diluted EPS

IQVIA has beaten adjusted diluted EPS consensus in each of the last 8 consecutive quarters, with surprise magnitudes of +0.6% to +2.8% — a consistent pattern of modest but reliable outperformance that reflects management’s conservative guidance philosophy.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year revenue and EBITDA guidance was reaffirmed at Q1 earnings (May 5, 2026) while EPS guidance was raised; no post-earnings guidance revisions have been issued, and management tone has been incrementally more positive at the June 2026 Jefferies conference, citing April EBP funding at approximately triple April 2025 levels.

No post-earnings guidance revisions have been issued via 8-K or press release since the May 5, 2026 Q1 earnings call. The June 11, 2026 8-K was a debt refinancing event (€950M senior notes due 2033) with no guidance implications. At the June 2026 Jefferies Healthcare Conference, management provided incrementally positive color — disclosing that April 2026 EBP funding was approximately triple April 2025 levels and that FSP as a share of recent bookings has been running meaningfully below its backlog share (high-teens percent), suggesting a mix shift back toward full-service outsourcing — but did not formally revise guidance. FX assumptions are locked to May 4, 2026 rates for both Q2 and full-year guidance.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have been remarkably stable since the Q1 print — EPS consensus moved less than 0.1% in either direction — suggesting the street is tracking guidance closely with minimal divergence; the lack of upward revision despite strong leading indicators (EBP funding, peer bookings) represents potential cushion rather than risk.

Source: Visible Alpha Consensus and Actuals Data. Estimate as of May 8, 2026 represents the post-Q1 print baseline (approximately 5 trading days after May 5, 2026 earnings). Current consensus as of July 27, 2026.

The near-zero estimate drift since the Q1 print is notable: despite management’s incrementally positive commentary at the June 2026 Jefferies conference (April EBP funding ~3x year-over-year, FSP mix shifting toward full-service), the street has not revised estimates upward. This creates an asymmetric setup — if Q2 bookings recover as peer data suggests, there is room for both an EPS beat and upward FY estimate revisions, while the downside scenario (bookings miss) is already partially discounted in the stock’s below-historical-average multiple.

5. Stock Performance

Key Takeaway: IQV’s +20.9% gain since the May 5 Q1 earnings date has been driven primarily by multiple re-expansion (+11.3% on P/E over 1 month, +25.1% over 3 months) rather than estimate revisions, which have been flat; the stock has meaningfully outperformed both XLV (+12.4%) and the S&P 500 (+2.1%) over the same period, but the multiple remains below historical averages at ~15x NTM P/E, suggesting the re-rating is not yet complete.

IQV vs. XLV vs. S&P 500 — Indexed Performance Since May 5, 2026 (Last Earnings Date)

Source: Yahoo Finance / Stock Price Data. Indexed to 100 at May 5, 2026 close ($176.42 IQV, $145.30 XLV, $723.77 SPY). July 28, 2026 reflects pre-market/intraday price of $213.22. Key events marked: ICON Q1 2026 earnings release (May 28), IQV €950M senior notes offering (Jun 11), ICON Q1 2026 earnings call (Jun 24), Medpace Q2 2026 earnings (Jul 22).

Performance decomposition: Over the 3-month window, IQV’s +31.4% gain was driven by ~+25.1% multiple expansion (NTM P/E from 12.23x to 15.30x) and only modest estimate contribution, consistent with a sentiment/re-rating recovery rather than fundamental earnings revision. The stock still trades at a meaningful discount to its pre-2024 disruption multiple, suggesting further re-rating potential if Q2 bookings confirm the demand recovery narrative.

6. Peer Commentary & Q2 2026 Read-Throughs

Key Takeaway: Both ICON (Q1 2026 earnings call, June 24, 2026) and Medpace (Q2 2026 earnings, July 22, 2026) delivered commentary that is unambiguously positive for IQVIA’s Q2 setup — ICON flagged Q2 as a “notably strong signing quarter” with biotech RFP volumes surging, while Medpace reported a record net bookings quarter (1.13x book-to-bill) driven by sharply lower cancellations and broad-based EBP funding.

Methodology note: Only commentary explicitly pertaining to Q2 2026 trends (April–June 2026) or disclosed after each peer’s last earnings call is included below. ICON’s Q1 2025 and Q4 2025 earnings commentary about those historical periods is excluded. Medpace’s Q2 2026 results (reported July 22, 2026) are included in full as they directly cover the same reporting quarter as IQV. Limitations: ICON and Medpace are smaller, more CRO-focused peers; IQVIA’s larger scale, commercial segment, and data/analytics mix may produce different outcomes even in the same demand environment.

ICON plc (ICLR) — Q1 2026 Earnings Call (June 24, 2026)

Reporting period covered: Q1 2026 (calendar Q1 2026). Commentary below pertains to Q2 2026 forward-looking statements made on the June 24, 2026 call.

• Q2 Bookings: CEO Barry Bell stated Q2 is “looking like a very strong quarter for signing” and expects “a significant shift in that number in the Q2 print.” He characterized Q2 as “what I suspect will be a notably strong signing quarter.” The direct fee book-to-bill is expected to remain “in 1.2x territory” in Q2.
• Read-through for IQV: Strong industry-wide signing activity in Q2 supports the thesis that IQV’s Q1 book-to-bill of 1.04x was an anomaly driven by pass-through mix rather than demand weakness. A recovery toward 1.10–1.15x is plausible.
• Biotech RFP Surge: Bell noted “biotech has a notably strong input in Q2 RFP flow” with “very significant increases in RFP volumes” from biotech specifically, even as large pharma RFP flow “probably drops a little in Q2.”
• Read-through for IQV: Consistent with IQVIA’s own disclosure that EBP funding reached ~$25B in Q1 2026 (nearly double Q1 2025) and April 2026 EBP funding was ~3x April 2025. Biotech RFP surge is a leading indicator for IQV’s EBP bookings in Q2 and beyond.
• Phase III Skew: Phase III trials in Q2 awards were described as “up around 38–39%” with average study sizes increasing substantially.
• Read-through for IQV: Larger, more complex Phase III trials favor integrated CROs like IQVIA with global scale and therapeutic depth. This mix shift is structurally positive for IQV’s revenue per study and margin profile.
• Cancellations: Bell indicated Q2 cancellations will “take a bit” but “certainly nothing like the concerning levels of cancellations we saw in the past,” with a normal range of $500–$600M.
• Read-through for IQV: Normalized cancellations across the industry support IQV’s own Q1 commentary that cancellations returned to historical averages. No incremental risk flagged.
• Margin Outlook: CFO Nigel Clarkin guided Q2 EBITDA margin of “somewhere around 16%,” representing ~50bps sequential improvement, driven by mix improvement and cost actions.
• Read-through for IQV: Industry-wide margin progression supports IQV’s own guidance for reported margins to “flip to positive” as the year progresses, with operational productivity programs more than offsetting non-operational headwinds.
• Full-Year Guidance: ICON reiterated FY 2026 EPS guidance of $10–$11, noting that strong bookings in Q4 2025, Q1 2026, and expected Q2 2026 are “much more relevant for 2027 than 2026.”
• Read-through for IQV: The bookings-to-revenue lag dynamic applies equally to IQVIA — strong Q2 bookings would be a 2027 revenue catalyst, not a 2026 revenue driver, consistent with IQV’s unchanged FY 2026 revenue guidance.

Medpace Holdings (MEDP) — Q2 2026 Earnings (July 22, 2026)

Reporting period covered: Q2 2026 (April–June 2026) — directly covers the same quarter IQV is reporting. Medpace is a pure-play CRO focused on small-to-mid-size biotech/pharma clients.

• Record Net Bookings: Medpace reported Q2 2026 net new business awards of $795.7M, up 28.2% year-over-year, resulting in a 1.13x net book-to-bill — a record quarter for net bookings.
• Read-through for IQV: A record bookings quarter at Medpace, driven by broad-based demand, is a strong positive read-through for IQV’s Q2 bookings recovery. If IQV’s book-to-bill recovers from 1.04x toward 1.10–1.15x (as management implied was the “normal” level absent pass-through distortion), it would be consistent with the industry-wide trend.
• Cancellations Sharply Lower: Cancellations were “well behaved” in Q2 and “came down quite a bit” from elevated Q1 levels. The reduction in cancellations was “more than half the driver” of net bookings growth from Q1.
• Read-through for IQV: Industry-wide cancellation normalization is a direct positive for IQV’s net bookings and backlog stability. IQV’s Q1 cancellations were already described as “within the normal range”; if Q2 follows Medpace’s pattern, IQV’s net bookings should benefit.
• RFP Flow: RFPs were “up meaningfully on a sequential basis” and “up substantially year-over-year,” with quality described as “good and improved.”
• Read-through for IQV: Consistent with IQV’s own Q1 disclosure of high-single-digit RFP flow growth year-over-year. Continued RFP strength in Q2 supports IQV’s mid-to-high single-digit qualified pipeline growth trajectory.
• Oncology Resurgence: Oncology represented “over half of overall bookings” in Q2 2026, with Medpace noting oncology “has come back quite a bit” while metabolic/cardiometabolic programs declined.
• Read-through for IQV: IQVIA has deep oncology capabilities and has been actively winning oncology mandates (e.g., Phase III oncology study win cited on Q1 call). An oncology-led bookings environment plays to IQV’s therapeutic strengths.
• Broad EBP Funding: Management noted “a lot of clients that have had recent funding” with funding “a lot broader rather than just a few companies getting quite a bit more money.” Decision-making trajectory has “improved with the funding environment.”
• Read-through for IQV: Broad-based EBP funding (vs. concentrated) is more durable and supports IQV’s EBP bookings diversification. Consistent with IQV’s disclosure of April 2026 EBP funding at ~3x April 2025 levels.
• Business Environment: Described as “strong” in Q2 2026 and “constructive into July.” The market has “gotten stronger over the last few quarters.”
• Read-through for IQV: A constructive July environment is directly relevant to IQV’s Q2 results (quarter ended June 30) and provides early positive color on Q3 2026 demand trends.
• Medpace Q2 2026 Financial Results (direct data point): Revenue $707.3M vs. consensus $689.2M (beat); EBITDA $153.4M vs. consensus $147M (beat); book-to-bill 1.13x; full-year EBITDA guidance raised to $618–$642M from $605–$635M.

Limitations of Peer Read-Throughs: (1) ICON and Medpace are smaller, more CRO-pure-play peers; IQVIA’s commercial segment (~42% of revenue) and data/analytics mix have no direct peer analog. (2) Medpace’s client base skews heavily toward small-to-mid biotech; IQVIA’s backlog is ~65% large pharma, which may exhibit different Q2 booking dynamics. (3) Medpace’s record bookings were partly driven by unusually low cancellations — a volatile and unpredictable variable. (4) ICON’s Q2 commentary was forward-looking (made June 24); actual ICON Q2 results have not yet been reported. (5) Quantitative figures from ICON’s call (e.g., “38–39%” Phase III increase) may contain transcription imprecision.

7. Material News & Developments

Key Takeaway: The most important post-Q1 development is the June 2026 Jefferies conference disclosure that April 2026 EBP funding was approximately triple April 2025 levels — the strongest leading-indicator signal yet for future R&DS bookings; the €950M debt refinancing is balance-sheet-neutral and does not affect the earnings setup.

• June 2026 — Jefferies Healthcare Conference (Management Commentary): Management disclosed that April 2026 EBP funding was approximately triple April 2025 levels, extending the near-record Q1 2026 trend ($25B, nearly double Q1 2025). FSP as a share of recent bookings has been running meaningfully below its backlog share (high-teens percent), signaling a mix shift back toward full-service outsourcing as trial complexity increases. Management also provided new specificity on commercial outsourcing: large pharma increasingly outsourcing commercialization of legacy drugs in overseas markets (South America, Europe, Asia) to IQVIA, with significant multi-year engagements from top-10 pharma.
• Implication: Strongest leading-indicator signal for Q2 and H2 2026 R&DS bookings; FSP mix shift is a structural positive for revenue quality and margins.
• June 11, 2026 — IQVIA Issues €950M Senior Notes Due 2033 (8-K): IQVIA Inc. (wholly owned subsidiary) completed issuance of €950M in 4.625% senior notes due June 15, 2033. Net proceeds used to refinance existing indebtedness. First interest payment due December 15, 2026.
• Implication: Balance-sheet-neutral refinancing; extends debt maturity profile and reduces near-term refinancing risk. No impact on Q2 2026 earnings guidance. Net leverage was 3.62x at Q1 end.
• May 5, 2026 — Q1 2026 Earnings Beat & EPS Guidance Raise: Revenue $4.151B (+8.4% reported, +6.0% constant currency, +4% organic) exceeded guidance high end; Adj. EPS $2.90 exceeded guidance high end; FCF $491M = 100% of adjusted net income (+15% YoY); R&DS backlog record $34.2B; NTM backlog revenue $8.9B (+7.6% YoY); $552M shares repurchased in Q1 with ~$1.2B remaining authorization. Full-year EPS guidance raised to $12.65–$12.95.
• Implication: Sets a high-quality baseline for Q2; management’s “surprised by strength across every metric” language is the most bullish tone in several years.
• Q1 2026 — Duke Clinical Research Institute Strategic Collaboration: New partnership to advance clinical research in obesity and cardiometabolic conditions, combining IQVIA’s scale (120+ obesity trials, 90,000+ patients enrolled including all FDA-approved GLP-1 therapies) with Duke’s academic rigor. Management noted the collaboration was already generating pipeline and early wins in Q2 2026.
• Implication: Positions IQVIA in the high-growth GLP-1/obesity trial space; early Q2 wins suggest incremental bookings contribution.
• Q1 2026 — AI Agent Deployment & IQVIA.ai Launch: 192 AI agents deployed across 64 use cases; IQVIA.ai agentic portal unveiled at NVIDIA GTC; 19 of top 20 pharma using IQVIA agents. Analytics & consulting (theoretically most AI-vulnerable) achieved best growth in 3 years with record pipeline. Management confirmed zero trials lost to any AI tool.
• Implication: AI is a demand creator (not disruptor) for IQVIA’s commercial segment; record analytics pipeline is a Q2 revenue tailwind.
• July 22, 2026 — Medpace Q2 2026 Results (Peer Read-Through): Record net bookings of $795.7M (+28.2% YoY), 1.13x book-to-bill; revenue $707.3M beat consensus $689.2M; EBITDA $153.4M beat consensus $147M; full-year EBITDA guidance raised. Business environment described as “strong” and “constructive into July.”
• Implication: Most timely and direct positive read-through for IQV’s Q2 bookings and demand environment.
• July 8, 2026 — IQVIA Announces Q2 2026 Results Date (Press Release): Confirmed Q2 2026 results before market open July 28, 2026; conference call at 9:00 a.m. ET. Webcast and replay available at ir.iqvia.com.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or sells by IQVIA insiders since the Q1 2026 earnings date; all Form 4 filings in the period reflect routine non-employee director deferred share acquisitions under the Non-Employee Director Deferral Plan — these are compensation-driven, not discretionary, and carry no informational signal.

Source: SEC Form 4 filings via SEC EDGAR. All transactions are Code ‘A’ (award/acquisition) under the Non-Employee Director Deferral Plan. Deferred shares convert to common stock when the director ceases to be a director, upon a change in control, or upon death. None of the transactions were made pursuant to a Rule 10b5-1 plan. No open-market purchases (Code P) or sales (Code S) were filed by any IQVIA insider in the period from May 5, 2026 through July 27, 2026. The absence of discretionary insider selling ahead of earnings is a mild positive signal, though the absence of open-market buying is also notable given the stock’s below-historical-average valuation.